MIMEDX GROUP, INC.(MDXG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,950 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in MDXG
Events flagged as statistical outliers against MDXG's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-07-29
MDXG quality score dropped 13 points (56→43) on a new filing
View source filing →
MDXG Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for MIMEDX GROUP, INC. (MDXG), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDXG at 43.9/100 on a 32-signal composite quality model, placing it at rank #1,950 of 2,962 stocks — the bottom half of the AI-ranked universe. MDXG scores in the top quartile across earnings quality (97.4). Areas of concern include profitability (28.6) and revenue scale (32.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MIMEDX GROUP, INC. reports quarterly revenue of $64.4M, net income of $-14.8M. Top institutional holders of MDXG by reported 13-F value include Essex Woodlands Management, BlackRock, Trigran Investments, based on the most recent SEC filings. MDXG trades on the Nasdaq exchange and files with the SEC under CIK 1376339. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDXG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MIMEDX GROUP, INC. directly from SEC EDGAR. MIMEDX GROUP, INC.'s 13F Pro composite quality score has ranged between 20 and 70 since 2021, currently 43.9 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$64.4M
Net Income
Q2 2026
$-14.8M
ROIC
Q2 2026
-31.7%
D/E Ratio
Q2 2026
0.08
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+20.0% YoYNet Income
+14.5% YoYOperating Income
+8.5% YoYEPS (Diluted)
+14.3% YoYTotal Assets
+29.8% YoYTotal Debt
-2.5% YoYOp. Cash Flow
+11.8% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $418.6M +20.0% | $348.9M +8.5% | $321.5M +20.0% | $267.8M +10.7% | $242.0M -2.5% | $248.2M |
| Net Income | $48.6M +14.5% | $42.4M -27.2% | $58.2M +292.8% | $-30.2M -193.6% | $-10.3M +79.1% | $-49.3M |
| Operating Income | $63.9M +8.5% | $58.9M +58.6% | $37.1M +352.0% | $-14.7M -108.9% | $-7.1M +84.5% | $-45.4M |
| EPS (Diluted) | $0.32 +14.3% | $0.28 -24.3% | $0.37 +212.1% | $-0.33 -120.0% | $-0.15 +80.5% | $-0.77 |
| Total Assets | $342.7M +29.8% | $263.9M +10.4% | $239.0M +39.4% | $171.4M -8.8% | $187.9M -7.0% | $202.0M |
| Total Debt | $19.5M -2.5% | $20.0M -60.8% | $51.0M +2.0% | $50.0M +0.0% | $50.0M +0.0% | $50.0M |
| Operating Cash Flow | $74.0M +11.8% | $66.2M +147.2% | $26.8M +249.6% | $-17.9M -802.8% | $-2.0M +93.5% | $-30.3M |
| Free Cash Flow | — | — | $24.8M +227.7% | $-19.4M -273.2% | $-5.2M | — |
Get alerted when MDXG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MIMEDX GROUP, INC. including:
Top Institutional Holders of MDXG
Essex Woodlands Management, Inc.
$108.6M28,195,249 shBlackRock, Inc.
$46.8M12,154,466 shTrigran Investments, Inc.
$27.6M7,173,770 shSTATE STREET CORP
$21.5M5,578,920 shVANGUARD CAPITAL MANAGEMENT LLC
$20.0M5,187,053 shNantahala Capital Management, LLC
$18.4M4,767,552 shPARADIGM CAPITAL MANAGEMENT INC/NY
$15.7M4,073,100 shGEODE CAPITAL MANAGEMENT, LLC
$12.1M3,143,488 shGOLDMAN SACHS GROUP INC
$10.3M2,665,562 shAQR CAPITAL MANAGEMENT LLC
$9.5M2,467,005 sh
| Fund | Value | Shares |
|---|---|---|
| Essex Woodlands Management, Inc. | $108.6M | 28,195,249 |
| BlackRock, Inc. | $46.8M | 12,154,466 |
| Trigran Investments, Inc. | $27.6M | 7,173,770 |
| STATE STREET CORP | $21.5M | 5,578,920 |
| VANGUARD CAPITAL MANAGEMENT LLC | $20.0M | 5,187,053 |
| Nantahala Capital Management, LLC | $18.4M | 4,767,552 |
| PARADIGM CAPITAL MANAGEMENT INC/NY | $15.7M | 4,073,100 |
| GEODE CAPITAL MANAGEMENT, LLC | $12.1M | 3,143,488 |
| GOLDMAN SACHS GROUP INC | $10.3M | 2,665,562 |
| AQR CAPITAL MANAGEMENT LLC | $9.5M | 2,467,005 |
Companies Similar to MDXG
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Bioventus Inc.
TELA Bio, Inc.
CONMED Corp
Teladoc Health, Inc.
HAEMONETICS CORP
NRC HEALTH
Alkermes plc.
AtriCure, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MDXG on your watchlist
Track score changes the day MIMEDX GROUP, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MDXG a good stock to buy?
13F Pro's AI-powered analysis of MIMEDX GROUP, INC. (MDXG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDXG are available on the MDXG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MDXG is classified as a small company.
Which hedge funds own MDXG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDXG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MIMEDX GROUP, INC.'s investment landscape.